CD4+ T cells, long regarded as supporting actors in cancer immunity, are emerging as central regulators of tumor control and ...

An enigmatic type of circulating tumor cell called a dual-positive (DP) cell is associated with shorter survival time in patients with advanced breast cancer, according to a study led by investigators ...

Cancer immunotherapy has transformed oncology, yet many patients fail to respond or eventually develop resistance.

A new review article highlights the transformative role of circular RNA (circRNA) in cancer, revealing its potential as both a key player in tumor biology and a promising avenue for future therapies.

Hepatobiliary and pancreatic tumors represent a critical area of oncological research due to their aggressive nature, limited ...

A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.

Immune checkpoint inhibitors targeting PD-1 and PD-L1 have revolutionized cancer therapy, delivering long-term survival benefits in several malignancies. However, nearly half of patients show limited ...

Molecularly targeted therapies are increasingly relevant in clinical oncology, as they enable the selective modulation of specific biologic targets—such as enzymes or receptors—by inhibiting or ...

The Liu Lab investigates cancer as a dynamic system shaped by interactions between tumor cells, their microenvironment, and intrinsic stress-response pathways. Our work focuses on identifying ...

A young pregnant patient assumed abdominal pain and rectal bleeding was from her pregnancy. She was diagnosed with Stage IV ...